COMMUNIQUÉS West-GlobeNewswire
 
      -   
  Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares27/10/2025
-   
  New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus26/10/2025
-   
  New Global Coalition Launches to Address the Hidden Threat of RSV in Adults26/10/2025
-   
  MapLight Therapeutics Announces Pricing of Initial Public Offering26/10/2025
-   
  Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline26/10/2025
-   
  Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy26/10/2025
-   
  mediCAD® 8 Revolutionizes Orthopedic and Trauma Planning with Intelligent AI Integration26/10/2025
-   
  Polpharma Group annonce un changement de direction – Sebastian Szymanek nommé nouveau président26/10/2025
-   
  Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 202525/10/2025
-   
  Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions25/10/2025
-   
  Avacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets25/10/2025
-   
  Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease25/10/2025
-   
  Quell Therapeutics to Unveil Promising Data for QEL-005, a Novel CAR-Treg Cell Therapy for Complex Autoimmune Diseases, at ACR Convergence 202525/10/2025
-   
  Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases25/10/2025
-   
  Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 202525/10/2025
-   
  ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium25/10/2025
-   
  Aletheia Capital Endeavours Launches RepIntel, a Campaign-Grade Platform to Accelerate Global Access to Therapies25/10/2025
-   
  Prenetics Global Limited Announces Proposed Public Offering25/10/2025
-   
  Enovis announces webcast and conference call for Third Quarter 2025 Results and participation in upcoming investor conferences24/10/2025
Pages